Daiichi Sankyo

    Daiichi Sankyo Co., Ltd. history, profile and corporate video

     Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the Daiichi Sankyo Group and Ranbaxy Group segments. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is head headquartered in Tokyo, Japan.

    Daiichi Sankyo History

    Daiichi Sankyo was established in 2005 through the merger of Sankyo Company, Limited (三共株式会社 Sankyō Kabushiki Kaisha?) and Daiichi Pharmaceutical Company, Limited (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha?), which were century-old pharmaceutical companies based in Japan.


    In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.

    On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.

    In June 2008, Daiichi Sankyo acquired U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company’s anticancer portfolio.

    On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkeley, California-based pharmaceutical start-up company for $805 million and an additional $130 million in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (Roche licensed) drug.”

    *Information from and

    **Video published on YouTube by “Daiichi Sankyo Europe GmbH



    Related videos